SIETES :: 92796 citas

Resultados de la búsqueda por INMUNOSUPRESION REFINAR BÚSQUEDA

1.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

2.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: A retrospective cohort study. Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102649]

3.

Anónimo. Saccharomyces boulardii probiotics: Do not use in critically ill or immunocompromised patients. Estonia . WHO Drug Information 2018;32:19. [Ref.ID 102623]

4.

Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel Jr EF, Grijalva CG. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case–control study. Ann Intern Med 2018;186:20 de marzo. [Ref.ID 102456]

5.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

6.

Wadström H, Frisell T, Askling J, for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. A nationwide cohort study from Sweden. JAMA Intern Med 2017;177:1605-12. [Ref.ID 102143]

7.

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]

8.

Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]

9.

McKinnon R, Ward M. Safety considerations of biosimilars. Australian Prescriber 2016;39:188. [Ref.ID 101019]

10.

Anónimo. Idelalisib (Zydelig): restricciones temporales de uso para prevenir infecciones graves mientras se realiza la revaluación europea del balance beneficio-riesgo . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:18 de marzo. [Ref.ID 100074]

11.

12.

Assassi S. Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer. BMJ 2016;352:i472. [Ref.ID 100032]

13.

14.

Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum 2016;68:56-66. [Ref.ID 99975]

15.

Andersen NN, Pasternak B, Andersson M, Nielsen NM, Jess T. Risk of demyelinating diseases in the central nervous system in patients with inflammatory bowel disease treated with tumor necrosis factor inhibitors. JAMA Intern Med 2015;175:1990-2. [Ref.ID 99751]

16.

Andersen NN, Pasternak B, Friis-Moller N, Andersson M, Jess T. Association between tumour necrosis factor-a inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015;350:h2809. [Ref.ID 99191]

17.

Anónimo. Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia. Drug Safety Update 2015;8:2. [Ref.ID 98886]

18.

Anónimo. Anti-inflammatoires non stéroïdiens: infections graves, fasciites cervicales. Prescrire 2014;34:832-3. [Ref.ID 98465]

19.

Anónimo. Gliptines: pemphigoïdes bulleuses. Prescrire 2014;34:829. [Ref.ID 98462]

20.

Anónimo. Ofatumumab (Arzerra): screen for hepatitis B virus before treatment. Drug Safety Update 2014;7:A2. [Ref.ID 97288]